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ANTIGEN-DEPENDENT SUPPRESSION OF GRAFT VERSUS HOST DIS-
EASE BY Foxp3-INDUCED REGULATORY T CELLS IN TRANSPLANTA-
TION
Albert, M.H.1, Liu, Y.2, Anasetti, C.3, Yu, X.-Z.3 1Pediatric Hematol-
ogy/Oncology, Dr. von Haunersches Kinderspital, Munich, Germany;
2Department of Medicine, University of Washington, Seattle, WA;
3Experimental Therapeutics Program, H. Lee Mofﬁtt Cancer Center &
Research Institute, Tampa, FL.
Adoptive transfer of polyclonal CD4CD25 regulatory T cells
(Tregs) can tolerize transplantation alloresponses and prevent le-
thal acute graft-versus-host disease (GVHD). For optimal suppres-
sive function, Tregs need to be activated via their T-cell receptors
(TCR), but the antigen speciﬁcity of wild type Tregs remains
elusive, and therefore controlling potency and duration of Treg
activity in the transplantation setting remains not feasible. In this
study, we used a murine lethal acute GVHD model system to test
the hypothesis that speciﬁcally activated, antigen-speciﬁc Tregs
induced by foxp3 transduction could suppress the response of T
effector cells to alloantigens in vitro and prevent GVHD in vivo
more effectively than polyclonal Tregs. We found that the sup-
pressive potential of TCR transgenic (Tg), antigen-speciﬁc
CD4CD25Tregs was much greater than that of polyclonal
Tregs in vitro and in vivo. When activated by their speciﬁc peptide
antigen, Tg Tregs protected 95% of recipients from lethal GVHD
even at ten times lower doses than polyclonal Tregs. To facilitate
the acquisition of larger numbers of antigen-speciﬁc Tregs, we
transduced naive CD4CD25- cells with foxp3, and observed that
these foxp3-induced Tregs also suppressed alloresponses in vitro
and prevented GVHD in vivo as effectively as naturally derived
CD4CD25 Tregs. To enhance translational feasibility, we
then used an antigen-speciﬁc CD4 Th1 T-cell clone as a source of
Tregs after transduction with foxp3, and found those Tregs to
effectively prevent GVHD in 90% of recipients. We further found
that prevention of GVHD via foxp3-induced Tregs was also de-
pendent on their activation by either a speciﬁc alloantigen ex-
pressed on recipient cells or by immunization with a speciﬁc
peptide antigen. The ﬁndings of this study provide a basis for the
concept that the onset and potency of alloresponse suppression in
GVHD can be regulated by using Tregs with known antigen
speciﬁcity. The novel evidence that antigen-speciﬁc T cell clones
can be used as the cell source for foxp3-induced Tregs further
improves the feasibility of using Tregs for modulating immune
responses in vivo. These data suggest a novel approach to control
induction of tolerance using Tregs as an adoptive immunotherapy
in allogeneic transplantation.
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MICROENVIRONMENT CONFERS RESISTANCE TO TRAIL MEDIATED AP-
OPTOSIS
Perez, L.E.1, Parquet, N.1, Nimmanapalli, R.2, Alsina, M.1,
Dalton, W.1, Anasetti, C.1 1H. Lee Mofﬁtt Cancer Center, Tampa, FL;
2M. D. Anderson Cancer Center, Houston, TX.
TNF-related apoptosis inducing ligand (TRAIL) is preferentially
cytotoxic against neoplastic cells with minimal toxicity to normal
cells. TRAIL plays a role in immune mediated tumor surveillance
and it is involved in graft versus tumor responses. The bone
marrow microenvironment provides tumor protection from che-
motherapy and extrinsic apoptotic pathways, a process known as
environmental mediated drug resistance (EM-DR). We hypothe-
size that EM-DR contributes to evade TRAIL mediated apoptosis
resulting in multiple myeloma (MM) progression. In this study we
have investigated whether EM-DR confers resistance to apoptosis
mediated by TRAIL in environmental in vitro models. Three drug
sensitive MM cell lines (RPMI-8266, U266 and MM1s) exhibit a
dramatic apoptosis resistance to recombinant human TRAIL (10
ng/mL) after 24 hours of exposure when directly attached to HS-5
stromal cells for 2 hours as determined by annexin/7-AAD staining
(Table 1). RPMI-8226 TRAIL-mediated apoptosis was demon-
strated dose- and time-dependent. Experiments in transwell assay
with RPMI-8226 in the upper well and HS-5 in the lower well
induced signiﬁcantly reduced apoptosis (8.9  5.4%) compared to
RPMI-8226 cells exposed to medium in lower well (37  16%)
after 4 hour treatment with TRAIL (10 ng/mL). Western blot
analysis of RPMI-8226 cells exposed to HS-5 for four hours in
transwell exhibited attenuated caspase-8, caspase-3 and PARP
cleavage. Direct contact of RPMI-8226 cells with ﬁbronectin did
not confer resistance to TRAIL. These ﬁndings suggest that sol-
uble factors produced by stromal cells contribute to TRAIL EM-
DR. Pretreatment of RPMI-8226 cells with proteosome inhibitor
bortezomib (10 nM) partially overcomes TRAIL EM-DR in cells
directly attached to HS-5 (1.5  0.7% apoptosis with TRAIL
versus 23.5  13.5% with TRAIL and bortezomib) and in trans-
well assays with HS-5 in lower well (8.9  5.4% apoptosis with
TRAIL versus 28.6  12.7% with TRAIL and bortezomib). Bort-
ezomib up-regulated TRAIL receptor-2 (DR5) mRNA expression
in RPMI-8226 cells, but did not increase DR5 protein expression
as determined by Western blot and ﬂow cytometry. We hypothe-
size that NF-B inactivation by bortezomib reduces transcription
of genes that mediate TRAIL-EM-DR. Mechanistic studies eluci-
dating TRAIL EM-DR are under investigation with the purpose to
identify novel targets to enhance anti-tumor activity of TRAIL
immune surveillance in vivo and to enhance anti-MM graft versus
tumor responses (Table 1).
Table 1. Adhesion of RPMI-8226, U266 and MM1s Myeloma
Cells to HS-5 Stromal Cells Attenuates TRAIL-Mediated Apoptosis
Suspension 75  10% 11  2.7% 25  1.7%
Direct adhesion to HS-5
stromal cells
12  1.8% 3.5  1% 4  0.7%
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A SINGLE MINOR HISTOCOMPATIBILITY ANTIGEN AELLNIPFLY EN-
CODED BY UGT2B17 IS PRESENTED BY HLA-A2902, B4402 AND
B4403
Terakura, S.1, Murata, M.1,2, Warren, E.H.2, Sette, A.3, Naoe, T.1,
Riddell, S.R.2 1Department of Hematology, Nagoya University Gradu-
ate School of Medicine, Nagoya, Aichi, Japan; 2Program in Immunology,
Fred Hutchinson Cancer Research Center, Seattle, WA; 3Vaccine Dis-
covery, La Jolla Institute for Allergy and Immunology, San Diego, CA.
T cell responses to minor histocompatibility (H) antigens are
mediators of GVHD and the GVL effect. We identiﬁed a minor H
antigen encoded by the UDP-glycosyltransferase 2 family,
polypeptide B17 (UGT2B17) gene, which is presented by HLA-
A2902 and recognized by a CD8 cytotoxic T lymphocyte (CTL)
clone PL8 isolated from a post-transplant patient with the HLA
type -A0201, A2902, B4403, B4402, Cw5, DR3, DR11. The
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immunogenicity of UGT2B17 results from absent expression in
donor cells due to a homozygous deletion of the UGT2B17 gene.
Here, we identify the speciﬁcity of an HLA-B4403-restricted
CTL clone PL10 isolated from the same patient. In cytotoxicity
assays against a panel of EBV transformed lymphoblastoid cells
(B-LCL), PL10 CTL exhibited the identical recognition pattern
against HLA-A2902- and B4403-positive B-LCL as the HLA-
A2902 restricted PL8 CTL. These data suggested PL10 may
recognize a peptide presented by B4403 that is also encoded by
the UGT2B17 gene or by a gene whose expression is linked to
UGT2B17. To examine the possibility that UGT2B17 encoded the
PL10 antigen, B-LCL from B4403-positive and UGT2B17-neg-
ative individuals were transfected with UGT2B17 cDNA and ex-
amined for recognition by PL10. PL10 CTL lysed the UGT2B17
transfectants and also lysed B-LCL from UGT2B17-positive,
B4403-negative individuals if these B-LCL were transfected with
HLA-B4403. Thus, PL10 recognized a peptide encoded by the
UGT2B17 gene and presented by B4403. Analysis of target cells
transfected with truncations of UGT2B17 and pulsed with syn-
thetic peptides identiﬁed AELLNIPFLY (half-maximal lysis: 50
nM), as the peptide recognized by PL10, which is identical to the
peptide presented by HLA-A2902 but recognized by PL8 CTL.
Although B4403-negative/B4402-positive, UGT2B17-positive
B-LCL were not lysed by PL10, HLA-B4402 and B4403 differ
by only a single amino acid that has minimal impact on peptide
binding. Indeed, in a peptide binding assay, AELLNIPFLY
bound B4402 and B4403 with equally high afﬁnity (IC50s of
5.0 and 2.7 nM, respectively), demonstrating a single peptide
AELLNIPFLY encoded by UGT2B17 can be presented by
HLA-A2902, B4402 and B4403, and may serve as an immu-
nodominant minor H antigen in UGT2B17 disparate individu-
als with these HLA alleles.
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